ICU Medical, Inc.
Financials
Valuation Metrics
ICU Medical, Inc.'s Market Cap is $3.82B. At end of 2025 it was $3.52B. Ranked #1551 of 3,121 in US market (top 50%), #543 of 1,463 on NASDAQ (top 37%), #95 of 205 in Health Care Equipment & Services (top 46%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.82B | US#1,551/3,121 Sec#95/205 |
| Revenue | $2.16B | US#1,391/3,121 Sec#88/205 |
| Net Income | $30M | US#2,033/3,121 Sec#101/205 |
| Total Assets | $3.97B | US#1,607/3,121 Sec#75/205 |
| Net Assets | $2.15B | US#1,191/3,121 Sec#60/205 |
| Employees | 13,000 | US#745/3,121 Sec#57/205 |
| Value | ||
| P/E | 126.80x | US#2,135/3,121 Sec#110/205 |
| P/B | 1.77x | US#1,093/3,121 Sec#53/205 |
| P/S | 1.77x | US#1,179/3,121 Sec#79/205 |
| EV/EBITDA | 16.09x | US#1,648/3,121 Sec#68/205 |
| FCF Yield | 4.01% | US#1,631/3,121 Sec#88/205 |
| Profitability | ||
| ROE | 1.40% | US#2,064/3,121 Sec#109/205 |
| ROA | 0.76% | US#2,073/3,121 Sec#116/205 |
| Op. Margin | 5.04% | US#1,986/3,121 Sec#105/205 |
| Revenue Growth | -8.98% | US#2,591/3,121 Sec#191/205 |
| Financial Health | ||
| Debt Ratio | 84.55% | US#942/3,121 Sec#94/205 |
| Total Debt | $1.27B | US#1,415/3,121 Sec#75/205 |
| FCF | $153M | US#1,535/3,121 Sec#88/205 |
| Cash | $298M | US#1,421/3,121 Sec#80/205 |
| Current Ratio | 2.43x | US#1,012/3,121 Sec#98/205 |
| Net Debt/EBITDA | 3.27x | US#1,685/3,121 Sec#104/205 |
| Performance | ||
| 1Y Return | 14.76% | US#1,205/3,121 Sec#90/205 |
| 1M Return | -18.48% | US#2,891/3,121 Sec#195/205 |
| From 52W High | -20.85% | US#1,549/3,121 Sec#109/205 |
| 1Y MDD | -27.18% | US#1,205/3,121 Sec#43/205 |
| Trading | ||
| Volume | 315,550 shares | US#2,645/3,121 Sec#183/205 |
| Trading Value | $48M | US#1,606/3,121 Sec#114/205 |
| Per Share | ||
| EPS | $1.20 | US#1,612/3,121 Sec#85/205 |
| BPS | $86.10 | US#154/3,121 Sec#12/205 |
Company Info
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.